Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
MWN-AI** Summary
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company, has announced its inclusion in the Russell 3000® Index and the Russell 2000® Index after the close of U.S. markets on June 27, 2025. This milestone comes in light of the annual reconstitution of the Russell U.S. Indexes, as confirmed by updates on May 23 and May 30, 2025. The Russell 2000 tracks small-cap U.S. stocks, while the Russell 3000 encompasses the largest 3,000 U.S. equities, highlighting Monopar's significant growth and transformation over the past year.
The inclusion aligns Monopar with the Russell U.S. Indexes—benchmarks utilized by numerous investment managers and institutional investors to guide their active and passive strategies. As of May 2025, these indexes benchmark approximately $10.6 trillion in assets, indicating the potential heightened visibility and capital access for Monopar post-inclusion. Quan Vu, Monopar's Chief Financial Officer, expressed pride in this achievement, particularly emphasizing recognition for the late-stage drug candidate ALXN1840 for Wilson disease, a testament to the progress made by the company over the year.
Monopar Therapeutics is targeting unmet medical needs with innovative treatments, including radiopharmaceutical programs aimed at advanced cancers and ongoing clinical activities. The company remains focused on navigating the regulatory landscape while also working to secure funds for its continued development of promising therapies.
While the inclusion in prominent indexes signals a positive trajectory, Monopar acknowledges the inherent risks of the biopharmaceutical industry, including regulatory hurdles and market acceptance challenges. The company cautions investors that actual results may vary from projected outcomes and that they are committed to ongoing transparency regarding future developments.
MWN-AI** Analysis
Monopar Therapeutics Inc. (Nasdaq: MNPR) recently announced its inclusion in both the Russell 3000® and Russell 2000® Indexes, a significant milestone for the company. This marks an important transition for Monopar, which is a clinical-stage biopharmaceutical firm focused on developing innovative therapies, particularly its late-stage drug candidate ALXN1840 for Wilson disease.
Inclusion in these indexes not only enhances the company's visibility but also increases its accessibility to a broader base of institutional investors, given that approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes. This event usually leads to increased trading volume and interest from fund managers who track these indices, providing a potential boost to Monopar's stock price in the near term.
Investors should closely monitor Monopar’s progress following this inclusion. The success of its drug candidate and the ability to navigate the complexities of clinical trials and regulatory approvals will be crucial indicators of future performance. Market sentiment around biopharmaceuticals can be volatile, especially for those in the early stages of commercialization. Therefore, while the inclusion may present a short-term trading opportunity, investors should also consider the inherent risks associated with the biopharma sector, especially related to funding for continued development, competing with larger firms, and regulatory challenges.
As such, potential investors might view Monopar as a speculative but intriguing option for those looking to add small-cap biotech exposure to their portfolios, especially with the backdrop of its promising drug candidates. However, it's advisable to remain cautious and informed about ongoing developments, as well as broader market trends that could impact Monopar’s performance in the coming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical?stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000 ® Index, with automatic inclusion in the small-cap Russell 2000 ® Index, after the close of U.S. equity markets on June 27, 2025. The inclusion follows the initial announcement on Friday, May 23, and the subsequent update on Friday, May 30, 2025, in connection with the annual reconstitution of the Russell U.S. Indexes.
The Russell 2000 ® Index tracks the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000 ® Index – a market capitalization-weighted equity index representing the largest 3,000 U.S. stocks. Inclusion in the Russell 3000 ® Index also leads to automatic inclusion in the relevant growth and value style indexes. Membership remains in effect for one year until the next reconstitution.
Russell U.S. Indexes, provided by FTSE Russell, are widely used by investment managers and institutional investors as benchmarks for active and passive investment strategies. As of May 2025, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes.
“This is an important milestone for Monopar and reflects the significant transformation and growth we have experienced over the past year,” said Quan Vu, Monopar’s Chief Financial Officer. “We are honored to be joining the Russell U.S. Indexes, an achievement driven largely by the growing recognition of our late-stage ALXN1840 drug candidate for Wilson disease.”
For more information on the Russell 2000 ® Index and Russell 3000 ® Index and the annual reconstitution, please visit the “Russell Reconstitution” section on the FTSE Russell website.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers. For more information, visit: www.monopartx.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com
Follow Monopar on social media for updates:
X: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ**
How will the inclusion of Monopar Therapeutics Inc. (MNPR) in the Russell 3000 and Russell 2000 indices impact investor perception and stock liquidity moving forward?
What specific milestones does Monopar Therapeutics Inc. (MNPR) anticipate achieving with the ALXN1840 drug candidate for Wilson disease before the next annual reconstitution of the Russell U.S. Indexes?
Given the potential market acceptance challenges mentioned, how is Monopar Therapeutics Inc. (MNPR) planning to differentiate ALXN1840 from competitors in the biopharmaceutical landscape?
What are the implications of the $10.6 trillion in assets benchmarked against the Russell U.S. Indexes for Monopar Therapeutics Inc. (MNPR) in terms of attracting institutional investors post-inclusion?
**MWN-AI FAQ is based on asking OpenAI questions about Monopar Therapeutics Inc. (NASDAQ: MNPR).
NASDAQ: MNPR
MNPR Trading
5.23% G/L:
$60 Last:
235,718 Volume:
$58.57 Open:
